Teva Pharmaceuticals CEO to resign next year

October 18, 2006 16:31


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Teva Pharmaceutical Industries, Ltd., said on Wednesday that company President and CEO Israel Makov, 67, has announced his plans to retire next year. His successor, Shlomo Yanai, 55, will take his place as President and CEO Designate during the first part of 2007. Makov said he would stay on as a senior strategic advisor for the next two years, working with Yanai to facilitate a smooth leadership transition. "My 11 years at Teva have been a wonderful experience. I am gratified at the opportunity I have had to lead Teva through a very exciting period in its history, a period during which it has become a truly global company, and the industry leader," Makov said, wishing Yanai "every success" in his upcoming role. Eli Hurvitz, Chairman of the Board of Teva, said that "this is just the first opportunity of many that we will have to thank Israel Makov for the role he has played in dramatically increasing the scope and scale of Teva's business and solidifying our position as the world's leading generic pharmaceutical company."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection